Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New vaccines against RSV and bird flu enter human testing

NCT ID NCT07516418

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Apr 09, 2026 · Last updated May 01, 2026 · Updated 3 times

Summary

This early-stage study tests the safety and immune response of experimental vaccines against RSV (a common respiratory virus) and the H5 bird flu strain. About 570 healthy adults aged 18 to 49 will receive different vaccine formulas and be monitored for side effects and antibody levels over 6-7 months. The goal is to find safe and promising vaccine candidates for further development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.